CS-BLAP — classification system for long-acting products
Nanomath CS-BLAP platform, in collaboration with Univeristy of Washington TLC-ART program, is a focused consulting service for pharma and biotech teams developing long-acting (LA) drug products — injectables, implants, and depot formulations. We bring mechanistic modeling, IVIVC expertise, and regulatory experience to every stage of LA development.
LA pharmacology & modeling
Mechanistic PK/PD models for subcutaneous and intramuscular long-acting injectables, depot formulations, and implants. We build from release-rate characterization through systemic exposure prediction across multi-month dosing intervals — connecting formulation parameters directly to clinical outcomes.
LA IVIVC & flip-flop
In vitro–in vivo correlation development for long-acting systems, including flip-flop PK identification and deconvolution. We design the release experiments that give predictive power, and build IVIVC models that hold across formulation variants and species.
LA classification system
Biopharmaceutical classification frameworks adapted for long-acting products — mapping release rate, solubility, absorption window, and target tissue distribution into actionable development decisions. Use it to triage formulation candidates early and guide the IND strategy.
LA NAM integration
New approach methodology integration for long-acting product development: in silico absorption models, physiologically-based biopharmaceutics, and organ-on-chip data translation. Reduce animal studies and improve mechanistic confidence at the IND stage.
Engage with us
Tell us about your LA product, the development stage you're at, and the decision you need the model to support. We'll get back within one business day with a scoping conversation.